Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies.
Fiche publication
Date publication
janvier 2015
Journal
Journal of neuroimmunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Brun S, Beaino W, Kremer L, Taleb O, Mensah-Nyagan AG, Lam CD, Greer JM, de Seze J, Trifilieff E
Lien Pubmed
Résumé
Our objective was to develop a chronic model of EAN which could be used as a tool to test treatment strategies for CIDP. Lewis rats injected with S-palmitoylated P0(180-199) peptide developed a chronic, sometimes relapsing-remitting type of disease. Our model fulfills electrophysiological criteria of demyelination with axonal degeneration, confirmed by immunohistopathology. The late phase of the chronic disease was characterized by accumulation of IL-17(+) cells and macrophages in sciatic nerves and by high serum IL-17 levels. In conclusion, we have developed a reliable and reproducible animal model resembling CIDP that can now be used for translational drug studies.
Mots clés
Animals, Cell Proliferation, drug effects, Disease Models, Animal, Electrophysiology, Evoked Potentials, physiology, Interleukin-17, blood, Lymphocytes, metabolism, Macrophages, pathology, Male, Myelin P0 Protein, chemistry, Peptides, toxicity, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, blood, Rats, Rats, Inbred Lew, Sciatic Nerve, pathology, T-Lymphocytes, pathology
Référence
J. Neuroimmunol.. 2015 Jan 15;278:1-10